VEGFA and neoplasm: Preclinical data demonstrated that inhibition of Ang2 following primary tumour resection significantly reduced the metastatic burden and exerted an antiangiogenic response with stabilized residual vasculature in metastases, and that combining Ang2 antibody with low-dose metronomic chemotherapy interfering with the recruitment of the anti-VEGF resistance-conferring myeloid cells further improved the therapeutic benefit with fewer adverse effects than high-dose chemotherapy [295].